Loading...
XNYS
TEVA
Market cap32bUSD
Dec 04, Last price  
28.41USD
1D
2.08%
1Q
49.92%
Jan 2017
-21.63%
Name

Teva Pharmaceutical Industries Ltd

Chart & Performance

D1W1MN
XNYS:TEVA chart
P/E
P/S
1.97
EPS
Div Yield, %
Shrs. gr., 5y
0.72%
Rev. gr., 5y
-0.41%
Revenues
16.54b
+4.40%
5,250,400,0008,408,000,0009,408,000,00011,085,000,00013,899,000,00016,121,000,00018,312,000,00020,317,000,00020,314,000,00020,272,000,00019,652,000,00021,903,000,00022,385,000,00018,854,000,00016,887,000,00016,658,000,00015,878,000,00014,925,000,00015,846,000,00016,544,000,000
Net income
-1.64b
L+193.20%
1,072,300,000546,000,0001,952,000,000635,000,0002,000,000,0003,331,000,0002,759,000,0001,963,000,0001,269,000,0003,055,000,0001,588,000,000329,000,000-16,265,000,000-2,150,000,000-999,000,000-3,990,000,000417,000,000-2,353,000,000-559,000,000-1,639,000,000
CFO
1.25b
-8.85%
1,370,000,0002,058,000,0001,813,000,0003,231,000,0003,373,000,0004,136,000,0004,134,000,0004,572,000,0003,237,000,0005,127,000,0005,542,000,0005,225,000,0003,507,000,0002,446,000,000538,000,0001,216,000,000798,000,0001,590,000,0001,368,000,0001,247,000,000
Dividend
Nov 27, 20170.085 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
IPO date
Jan 01, 1951
Employees
34,004
Domiciled in
IL
Incorporated in
IL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT